Associate Professor Andrew Webb - Advanced Technology and Biology division

Associate Professor Andrew Webb - Advanced Technology and Biology division

Davis Auditorium
Start Time: 
Wed, 14/08/2019 - 1:00pm
End Time: 
Wed, 14/08/2019 - 2:00pm

Proteomics research in health and disease: Applications in basic research and beyond


Wednesday seminar​ hosted by Professor Guillaume Lessene

Clinical and biological phenotypes including cellular responses to stimuli arise from the composition of biomolecules and their organisation in tissue and or in cells. At present, our understanding of how these systems work at scale is neither comprehensive nor modellable, preventing prediction of phenotypes or cellular responses to stimuli. This presents two related challenges, firstly in defining the type molecular information needed to further our understanding, and secondly, creating the tools and methods required for their measurement and analysis. As it is only through their combined development will our ability to make predictions from molecular measurements move beyond what it is achievable today.

The WEHI Proteomic Laboratory is working to tackle these challenges, working as a collaborative resource with the specific aim of applying the next-generation of proteomics to important biological questions relevant to human health. We have seen large and exciting advancements in sample preparation, instrumentation and bioinformatics that are leading us to a more comprehensive understanding of posttranslational regulation, cell signalling and protein interactions. Our team is directly engaged in the conception, design and implementation of collaborators’ projects, to apply and further improve cutting-edge proteomics techniques that will drive and facilitate new discoveries in biology.

After receiving his PhD in Biochemistry at Monash University in 2005, Associate Professor Andrew Webb trained in Immunology, Virology and Mass Spectrometry.  His current research focuses on developing both accessible wet and dry lab tools with a focus on automation to further proteomics research and in doing so drastically increasing throughput and lowering the barriers to entry for medical researchers.